Setmelanotide 在获得性下丘脑肥胖中的试验
2026年7月16日 更新者:Rhythm Pharmaceuticals, Inc.
评估 Setmelanotide 在获得性下丘脑肥胖患者中的疗效和安全性的 3 期、双盲、随机、安慰剂对照试验
该试验的目的是了解 Setmelanotide 在改善 4 岁及以上患有获得性下丘脑肥胖症 (HO) 的患者的体重减轻、饥饿感和生活质量方面的效果。
为了确定 setmelanotide 的效果和安全性,HO 患者将每天注射 setmelanotide 或安慰剂,并完成长达 60 周的试验评估。
研究概览
研究类型
介入性
注册 (实际的)
143
阶段
- 第三阶段
联系人和位置
本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。
学习地点
-
-
Ontario
-
Toronto、Ontario、加拿大、M5G 1X8
- Hospital for Sick Children
-
-
-
-
-
Hamburg、德国、20246
- Universitaetsklinikum Hamburg-Eppendorf (UKE) - Ambulanzzentrum des UKE GmbH
-
München、德国、81667
- Medicover Neuroendokrinologie
-
Oldenburg、德国、26133
- University Children's Hospital, Klinikum Oldenburg
-
Ulm、德国、89075
- Universitaetsklinikum Ulm - Klinik fuer Kinder- und Jugendmedizin
-
-
-
-
Aichi-ken
-
Nagoya、Aichi-ken、日本、467-8602
- Nagoya City University Hospital
-
-
Nagano
-
Azumino、Nagano、日本、399-8288
- Nagano Children's Hospital
-
-
Tokyo
-
Minato、Tokyo、日本、105-8470
- Toranomon Hospital
-
-
-
-
Alabama
-
Birmingham、Alabama、美国、35233
- UAN Pediatric Endocrinology
-
-
California
-
San Diego、California、美国、92123
- Rady Children's Hospital
-
-
Colorado
-
Aurora、Colorado、美国、80045
- Children's Hospital Colorado
-
-
Florida
-
Gainesville、Florida、美国、32610-0296
- University of Florida
-
-
Illinois
-
Chicago、Illinois、美国、60611
- Ann and Robert H. Lurie Children's Hospital
-
-
Iowa
-
Iowa City、Iowa、美国、52242
- University of Iowa Stead Family Department of Pediatrics
-
-
Massachusetts
-
Boston、Massachusetts、美国、02115
- Brigham and Women's Hospital
-
Boston、Massachusetts、美国、02115
- Boston Children's Hospital
-
-
Minnesota
-
Saint Paul、Minnesota、美国、55102
- Children's Minnesota
-
-
New York
-
New York、New York、美国、10032
- Columbia University Irving Medical Center
-
New York、New York、美国、100029
- Icahn School of Medicine at Mount Sinai
-
-
Ohio
-
Columbus、Ohio、美国、43203
- Ohio State Wexner Medical Center
-
-
Oklahoma
-
Oklahoma City、Oklahoma、美国、73122
- Lynn Health Science Institute
-
-
Pennsylvania
-
Philadelphia、Pennsylvania、美国、19104
- Children's Hospital of Philadelphia
-
-
Tennessee
-
Nashville、Tennessee、美国、37232
- Vanderbilt University School of Medicine
-
-
Washington
-
Seattle、Washington、美国、98101
- Seattle Children's Hospital, Research and Foundation - Center for Integrative Brain Research
-
-
-
-
-
Birmingham、英国、B46NH
- Birmingham Women and Children's Hospital NHS Trust
-
Hull、英国、HU32RW
- Hull University Teaching Hospital
-
London、英国、WC1N 1EH
- UCL Great Ormond Street Institute of Child Health
-
-
-
-
-
Utrecht、荷兰、3584CS
- Prinses Maxima Center for Pediatric Oncology
-
-
参与标准
研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
4年 及以上 (孩子、成人、年长者)
接受健康志愿者
不
描述
关键纳入标准:
- 获得性下丘脑肥胖 (HO) 的书面证据
- 4岁及以上
- 与下丘脑损伤相关的体重增加和 ≥18 岁患者的 BMI ≥ 30 kg/m2 或 4 至 <18 岁患者的 BMI ≥ 年龄和性别的第 95 个百分位数
- 同意在整个研究期间和研究后 90 天内使用高效的避孕方式
关键排除标准:
- 普瑞德-威利综合征 (PWS) 或快速肥胖伴换气不足、下丘脑、自主神经失调、神经内分泌肿瘤综合征 (ROHHADNET) 的诊断
- 年龄≥18 岁的患者在过去 3 个月内体重减轻 >2% 或年龄 4 至 <18 岁的患者 BMI 降低 >2%
- 最近 2 年内的减肥手术或程序
- 严重精神疾病的诊断;任何自杀念头、企图或行为
- 目前有临床意义的肺部、心脏、代谢或肿瘤疾病
- 与黑色素瘤或黑色素瘤前皮肤病变相关的重要皮肤病学发现(不包括非侵入性基底或鳞状细胞病变)
- 皮肤癌或黑色素瘤的病史或家族史
- 在第一次试验剂量前 3 个月内参加任何使用研究药物/设备的临床试验
- 之前参加过涉及 setmelanotide 的临床试验或之前接触过 setmelanotide
- 无法遵守每日一次 (QD) 注射方案
- 如果是女性,怀孕和/或哺乳
- 在下丘脑损伤之前因其他遗传或综合症(例如 PPL [POMC、PCSK1、LEPR,统称]、BBS)而导致肥胖的患者。
- 如果接受激素替代疗法,剂量在筛选前至少保持稳定 2 个月
其他协议定义的包含/排除标准可能适用。
学习计划
本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:三倍
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:硫磺肽
随机化 2:1(Setmelanotide:安慰剂)
|
每日皮下注射溶液
其他名称:
|
|
安慰剂比较:安慰剂
随机化 2:1(Setmelanotide:安慰剂)
|
安慰剂与 setmelanotide 匹配用于每日皮下注射
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Pivotal Cohort: Mean Percent Change From Baseline in Body Mass Index (BMI) After 52 Weeks on a Therapeutic Regimen
大体时间:Baseline, after approximately 52 Weeks on a Therapeutic Regimen (up to approximately 60 weeks)
|
BMI was calculated as weight (kg)/height (m^2).
Least square (LS) mean and standard error (SE) were calculated using analysis of covariance (ANCOVA) model.
|
Baseline, after approximately 52 Weeks on a Therapeutic Regimen (up to approximately 60 weeks)
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Pivotal Cohort: Percentage of Participants With ≥5% Reduction From Baseline in BMI (≥18 Years of Age) or ≥0.2-point Reduction From Baseline in BMI Z-score (<18 Years of Age)
大体时间:After approximately 52 Weeks on a Therapeutic Regimen (baseline up to approximately 60 weeks)
|
BMI was calculated as weight (kg)/height (m^2).
BMI Z-Score calculated for participants <18 years old only is a measure of relative weight adjusted for child's age, sex and height at the time of data collection.
The Z-Scores were calculated using the World Health Organization's WHO 2007 BMI SAS Macro Package.
A Z-score of 0 is equal to the mean of a reference population (i.e., healthy, age and sex-matched individuals).
A decrease in BMI Z-score (< 0) indicates a reduction in BMI from Baseline whereas an increase in BMI-Z score (> 0) indicated an increase in BMI from Baseline.
Baseline was defined as the most recent measurement prior to the first administration of study drug.
Results below represent the percentage of estimated participants with either ≥5% BMI reduction or ≥0.2 point reduction in BMI Z-score by age in each treatment arm as calculated through the MIANALYZE SAS procedure.
|
After approximately 52 Weeks on a Therapeutic Regimen (baseline up to approximately 60 weeks)
|
|
Pivotal Cohort: Percentage of Participants With ≥5% Reduction From Baseline in BMI
大体时间:After approximately 52 Weeks on a Therapeutic Regimen (baseline up to approximately 60 weeks)
|
BMI was calculated as weight (kg)/height (m^2).
Results below represent the percentage of estimated participants with ≥5% BMI reduction in each treatment arm as calculated through the MIANALYZE SAS procedure.
|
After approximately 52 Weeks on a Therapeutic Regimen (baseline up to approximately 60 weeks)
|
|
Pivotal Cohort: Change From Baseline in Weekly Average Daily Most Hunger Score in Participants ≥12 Years of Age
大体时间:Baseline, after approximately 52 Weeks on a Therapeutic Regimen (up to approximately 60 weeks)
|
Change from baseline in hunger scores for participants ≥12 years of age with acquired hypothalamic obesity was evaluated.
Hunger score ranged from 0= "not hungry at all" to 10= "hungriest possible" on an 11-point numeric rating scale.
On Daily Hunger Questionnaire, each of the 2 items (average hunger and most hunger) was scored separately and averaged on weekly basis.
LSM and SE were calculated using ANCOVA model.
|
Baseline, after approximately 52 Weeks on a Therapeutic Regimen (up to approximately 60 weeks)
|
|
Pivotal Cohort: Percentage of Participants (≥12 Years of Age) With a ≥2-point Reduction From Baseline in the Weekly Average Daily Most Hunger Score
大体时间:After approximately 52 Weeks on a Therapeutic Regimen (baseline up to approximately 60 weeks)
|
Hunger score ranged from 0= "not hungry at all" to 10= "hungriest possible" on an 11-point numeric rating scale.
On Daily Hunger Questionnaire, each of the 2 items (average hunger and most hunger) was scored separately and averaged on weekly basis.
Results below represent the percentage of estimated participants ≥12 years of age with ≥2-point reduction in each treatment arm as calculated through the MIANALYZE SAS procedure.
|
After approximately 52 Weeks on a Therapeutic Regimen (baseline up to approximately 60 weeks)
|
|
Pivotal Cohort: Mean Change From Baseline in the Weekly Average of the Symptoms of Hyperphagia Composite Score in Participants ≥12 Years of Age
大体时间:Baseline, after approximately 52 Weeks on a Therapeutic Regimen (up to approximately 60 weeks)
|
Participants ≥12 years of age who were able to self-report were administered the Symptoms of Hyperphagia: Patient (Version 1.0).
The questionnaire consisted of 4 items related to the frequency of a participant's hunger symptoms on a scale (Never, 1 or 2 times, 3 or more times) over the past 24 hours.
The scores on this scale range from 0 to 2 with higher scores indicating more hyperphagia.
Daily composite score was derived as the sum of daily answered questions divided by the number of answered questions per day.
The weekly average of the daily composite scores equals to the sum of daily composite scores divided by the number of days with a composite score within the 7 identified days prior to the visit.
LSM and SE were calculated using ANCOVA model.
|
Baseline, after approximately 52 Weeks on a Therapeutic Regimen (up to approximately 60 weeks)
|
|
Pivotal Cohort: Percentage of Participants With a ≥10% Reduction From Baseline in BMI
大体时间:After approximately 52 Weeks on a Therapeutic Regimen (baseline up to approximately 60 weeks)
|
BMI was calculated as weight (kg)/height (m^2).
Results below represent the percentage of estimated participants with ≥10% BMI reduction in each treatment arm as calculated through the MIANALYZE SAS procedure.
|
After approximately 52 Weeks on a Therapeutic Regimen (baseline up to approximately 60 weeks)
|
|
Pivotal Cohort: Percentage of Participants With a ≥10% Reduction From Baseline in Body Weight
大体时间:After approximately 52 Weeks on a Therapeutic Regimen (baseline up to approximately 60 weeks)
|
Body weight was captured for analysis in kilograms.
Results below represent the percentage of estimated participants with ≥10% reduction in body weight in each treatment arm as calculated through the MIANALYZE SAS procedure.
|
After approximately 52 Weeks on a Therapeutic Regimen (baseline up to approximately 60 weeks)
|
|
Pivotal Cohort: Mean Percent Change From Baseline in Body Weight in Participants ≥18 Years
大体时间:Baseline, after approximately 52 Weeks on a Therapeutic Regimen (up to approximately 60 weeks)
|
Body weight was captured for analysis in kilograms.
LSM and SE were calculated using ANCOVA model.
|
Baseline, after approximately 52 Weeks on a Therapeutic Regimen (up to approximately 60 weeks)
|
|
Pivotal Cohort: Mean Change From Baseline in BMI Z-Score in Participants <18 Years of Age
大体时间:Baseline, after approximately 52 Weeks on a Therapeutic Regimen (up to approximately 60 weeks)
|
BMI was calculated as weight (kg)/height (m^2).
BMI Z-Score calculated for participants <18 years old only is a measure of relative weight adjusted for child's age, sex and height at the time of data collection.
The Z-Scores were calculated using the World Health Organization's WHO 2007 BMI SAS Macro Package.
A Z-score of 0 is equal to the mean of a reference population (i.e., healthy, age and sex-matched individuals).
A decrease in BMI Z-score (< 0) indicates a reduction in BMI from Baseline whereas an increase in BMI-Z score (> 0) indicates an increase in BMI from Baseline.
Baseline was defined as the most recent measurement prior to the first administration of study drug.
LSM and SE were calculated using ANCOVA model.
|
Baseline, after approximately 52 Weeks on a Therapeutic Regimen (up to approximately 60 weeks)
|
|
Pivotal Cohort: Mean Change From Baseline in Percent of BMI 95th Percentile in Participants <18 Years of Age
大体时间:Baseline, after approximately 52 Weeks on a Therapeutic Regimen (up to approximately 60 weeks)
|
BMI was calculated using participant's weight and height assessments, using the following formula: BMI = kg/m^2.
BMI percentile scores are measures of relative weight adjusted for child's age and gender.
The percent of the BMI 95th percentile score expresses the participant's BMI as a percentage of the Centers for Disease Control (CDC) 95th percentile reference population.
Baseline was defined as the most recent measurement prior to the first administration of study drug.
LSM and SE were calculated using ANCOVA model.
|
Baseline, after approximately 52 Weeks on a Therapeutic Regimen (up to approximately 60 weeks)
|
|
Pivotal Cohort: Percentage of Participants <18 Years of Age With ≥0.2-Point Reduction From Baseline in BMI Z-Score
大体时间:After approximately 52 Weeks on a Therapeutic Regimen (baseline up to approximately 60 weeks)
|
BMI was calculated as weight (kg)/height (m^2).
BMI Z-Score calculated for participants <18 years old only is a measure of relative weight adjusted for child's age, sex and height at the time of data collection.
The Z-Scores were calculated using the World Health Organization's WHO 2007 BMI SAS Macro Package.
A Z-score of 0 is equal to the mean of a reference population (i.e., healthy, age and sex-matched individuals).
A decrease in BMI Z-score (< 0) indicates a reduction in BMI from Baseline whereas an increase in BMI-Z score (> 0) indicates an increase in BMI from Baseline.
Baseline was defined as the most recent measurement prior to the first administration of study drug.
Results below represent the percentage of estimated participants with ≥0.2 point reduction in BMI Z-score in each treatment arm and the difference between the treatment arms as calculated through the MIANALYZE SAS procedure.
|
After approximately 52 Weeks on a Therapeutic Regimen (baseline up to approximately 60 weeks)
|
|
Pivotal Cohort: Percentage of Participants With BMI <30 kg/m^2 (Aged ≥18 Years) or <95th Percentile (Aged <18 Years) From Baseline
大体时间:After approximately 52 Weeks on a Therapeutic Regimen (baseline up to approximately 60 weeks)
|
BMI was calculated using participant's weight and height assessments, using the following formula: BMI = kg/m^2.
BMI Percentile scores are measures of relative weight adjusted for child's age and gender.
The percent of the BMI 95th percentile score expresses the participant's BMI as a percentage of the CDC 95th percentile reference population.
Baseline was defined as the most recent measurement prior to the first administration of study drug.
Results below represent the percentage of estimated participants with either BMI <30 kg/m^2 (aged ≥18 years) or <95th percentile (aged <18 years) in each treatment arm and the difference between the treatment arms as calculated through the MIANALYZE SAS procedure.
|
After approximately 52 Weeks on a Therapeutic Regimen (baseline up to approximately 60 weeks)
|
|
Pivotal Cohort: Mean Change From Baseline in Physical Functioning Score and Total Score on the Impact of Weight on Quality of Life-Lite (IWQOL)
大体时间:Baseline, after approximately 52 Weeks on a Therapeutic Regimen (up to approximately 60 weeks)
|
The IWQOL-Lite-Clinical Trials (administered to participants ≥18 years of age) is a validated 20-item self-report measure of obesity-specific quality of life questionnaire.
It assessed 2 primary domains of obesity-related health-related quality of life (HRQoL): physical (7 items) and psychosocial (13 items).
Each item was rated on a scale from 0 (worst) to 100 (best), with higher scores indicating better levels of functioning.
It provided composite scores for each domain, as well as a total score, all ranging from 0 (worst) to 100 (best).
Higher scores reflect better levels of functioning and quality of life.
LSM and SE were calculated using ANCOVA model.
|
Baseline, after approximately 52 Weeks on a Therapeutic Regimen (up to approximately 60 weeks)
|
|
Pivotal Cohort: Mean Change From Baseline in Total Score on the Impact of Weight on Quality of Life-Kids (IWQOL-Kids)
大体时间:Baseline, after approximately 52 Weeks on a Therapeutic Regimen (up to approximately 60 weeks)
|
The IWQOL-Kids (administered to participants between the ages of 11 and <18 years) is a validated 27-item self-report measure of weight-related quality of life for youth.
It provided a total score inclusive of 4 domains: physical comfort, body esteem, social life, and family relations.
Results below represent the total score, which is rated on a scale from 0 (worst) to 100 (best), with higher scores indicating better levels of functioning.
LSM and SE were calculated using ANCOVA model.
|
Baseline, after approximately 52 Weeks on a Therapeutic Regimen (up to approximately 60 weeks)
|
|
Pivotal Cohort: Mean Change From Baseline in Waist Circumference
大体时间:Baseline, after approximately 52 Weeks on a Therapeutic Regimen (up to approximately 60 weeks)
|
Waist circumference was captured for analysis in centimeters.
LSM and SE were calculated using ANCOVA model.
|
Baseline, after approximately 52 Weeks on a Therapeutic Regimen (up to approximately 60 weeks)
|
|
Pivotal Cohort: Change From Baseline in Systolic and Diastolic Blood Pressure
大体时间:Baseline, after approximately 52 Weeks on a Therapeutic Regimen (up to approximately 60 weeks)
|
Blood pressure was calculated in millimeters of mercury.
|
Baseline, after approximately 52 Weeks on a Therapeutic Regimen (up to approximately 60 weeks)
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
调查人员
- 学习椅:David Meeker, MD、Rhythm Pharmaceuticals, Inc.
出版物和有用的链接
负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。
一般刊物
- Miller JL, van Santen HM, Phillips SA, Hamilton J, Aberle J, Sathyapalan T, Mohamed Z, McCormack SE, Shoemaker AH, Kelsey MM, Ghalib L, Stalla G, Thaker VV, Habiby R, Ode KL, Wabitsch M, Dattani M, Abuzzahab MJ, Abdullatif H, Morgan R, Stefater-Richards M, Aroda VR, Friedrich C, Han JC, Ono H, Nagasaki K, Tanaka T, Isojima T, Arima H, Scimia C, Yuan G, Muller HL, Roth CL; TRANSCEND Trial Group. Setmelanotide for the Treatment of Acquired Hypothalamic Obesity. N Engl J Med. 2026 Jul 9;395(2):138-150. doi: 10.1056/NEJMoa2512275.
- Roth CL, Phillips SA, McCormack SE, Ode KL, Kelsey MM, Liu J, Ervin C, Mallya UG, Norcross L, Miller JL. Quality of life improvements with setmelanotide treatment in acquired hypothalamic obesity: TRANSCEND trial interview results from US participants. Front Behav Neurosci. 2026 Jul 15;20:1830070. doi: 10.3389/fnbeh.2026.1830070. eCollection 2026.
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始 (实际的)
2023年4月26日
初级完成 (实际的)
2025年3月18日
研究完成 (估计的)
2027年4月16日
研究注册日期
首次提交
2023年3月1日
首先提交符合 QC 标准的
2023年3月16日
首次发布 (实际的)
2023年3月20日
研究记录更新
最后更新发布 (实际的)
2026年8月10日
上次提交的符合 QC 标准的更新
2026年7月16日
最后验证
2026年7月1日
更多信息
与本研究相关的术语
关键字
其他相关的 MeSH 术语
其他研究编号
- RM-493-040
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
不
药物和器械信息、研究文件
研究美国 FDA 监管的药品
是的
研究美国 FDA 监管的设备产品
不
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.